impact factor, citescore
logo
 

Full Papers

 

Gastrointestinal dysmotility complicating Behçet’s syndrome: description of a newly recognised clinical phenotype


1, 2, 3, 4, 5

 

  1. The National Behçet’s Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK. desmond.kidd@nhs.net
  2. Apheresis Unit, Department of Haematology, Royal Free Hospital, London, UK.
  3. The National Behçet’s Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK.
  4. Department of Nuclear Medicine, Royal Free Hospital, London, UK.
  5. The National Behçet’s Syndrome Centre of Excellence, Royal London Hospital, Whitechapel, London, UK.

CER16940
2023 Vol.41, N°10
PI 2087, PF 2092
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 37902272 [PubMed]

Received: 23/06/2023
Accepted : 18/09/2023
In Press: 30/10/2023
Published: 30/10/2023

Abstract

OBJECTIVES:
Gastrointestinal dysmotility may arise in a variety of auto-immune and auto-inflammatory diseases and hitherto has not been described in Behçet’s syndrome (BS).
METHODS:
We present data on a cohort of seven patients under our care who presented with symptoms of and investigations compatible with an immune associated disorder of gastrointestinal motility, or enteric neuropathy.
RESULTS:
We describe the clinical features and investigation results. We undertook a trial of a novel treatment in the disease, apheresis, and noted a response not only to the enteric neuropathy but also to the systemic features of the disease, despite previous maximal immunosuppressive therapy in most cases.
CONCLUSIONS:
Gastrointestinal dysmotility may arise in BS and is effectively treated by apheresis. The mechanism by which this response is made immunologically requires to be elucidated in future studies.

DOI: https://doi.org/10.55563/clinexprheumatol/hjs8yp

Rheumatology Article